Patients with Thyroid Cancer Exhibit High Distress Levels
the Cancer Therapy Advisor take:
According to a study published in the journal Otolaryngology - Head and Neck Surgery, researchers from the Huntsman Institute in Salt Lake City, Utah, have found that patients with thyroid cancer have high distress levels.
For the retrospective cohort study, researchers sought to evaluate levels of psychosocial distress in patients with thyroid cancer and to analyze factors contributing to levels of distress. Researchers identified 118 patients with newly diagnosed thyroid cancer.
They found that 43.3% of those patients had significant psychosocial distress. Results also showed that patients with antidepressant medication use, self-report psychiatric history, and history of radiotherapy had higher levels of psychosocial distress.
A multivariate analysis showed that patients who endorsed emotional issues had a higher level of psychosocial distress.
The findings suggest that patients with thyroid cancer have high distress levels, and it is important to identify patients with high distress so that additional support can be offered during cancer therapy.
Patients with thyroid cancer have high distress levels.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Plastics and Cancer
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Emetogenic Potential of Antineoplastic Agents
- 20-Year Data Link High-Dose Chemotherapy and Hematopoietic Stem Cell Transplant to Survival Benefit in High-Risk Early Breast Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Reducing Trastuzumab Duration Lowers Costs by Nearly £10,000 in HER2-positive Breast Cancer
- Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer